Attune Neurosciences is a San Francisco-based, clinical-stage medical device company building what it calls the first wearable, non-invasive focused-ultrasound system for deep brain therapy. Its investigational headband, ATTN201, uses low-intensity transcranial focused ultrasound (tFUS) to reach precise deep-brain targets - like the central medial thalamus - while recording EEG and head movement, aiming to treat sleep and wake disorders, depression, addiction recovery, and other neurological and psychiatric conditions without drugs or surgery.
Rajiv Mahadevan is the co-founder and CEO of Attune Neurosciences, a San Francisco neurotechnology company building what it calls the world's first wearable, non-invasive ultrasound system for deep brain therapy. A UC Berkeley molecular biologist turned Stanford MBA, he spent two decades inside biotech and precision-medicine companies - 23andMe, Novo Nordisk, and his own venture Applied Immunology, which was acquired by Precision Medicine Group - before turning his attention to the skull. Attune's headband-shaped device aims low-intensity focused ultrasound at deep brain structures with MRI-guided precision, and it is backed by venture investors, the NIH, and the U.S. Special Operations Command.